Scientists restore partial sight in blind man

Published May 25, 2021
Scientists in Europe and the US recruited a man who had lost his sight due to an inherited photoreceptor disease 40 years ago and began treating him with optogenetic techniques. — Reuters/File
Scientists in Europe and the US recruited a man who had lost his sight due to an inherited photoreceptor disease 40 years ago and began treating him with optogenetic techniques. — Reuters/File

PARIS: Scientists have for the first time managed to partially restore the sight of a blind patient by altering his cells, according to the results of a groundbreaking study published on Monday.

The technique known as optogenetics, which has been developed in the field of neuroscience over the last 20 years, involves genetically altering cells so they produce more light-sensitive proteins.

In some cases of blindness, known as inherited photoreceptor diseases, light-sensing cells in the retina that use proteins to deliver visual information to the brain via the optic nerve progressively degenerate.

Scientists in Europe and the US recruited a man who had lost his sight due to an inherited photoreceptor disease 40 years ago and began treating him with optogenetic techniques.

This involved injections in his eye and several months of stimulation with light emitting goggles, which transformed images of the visual world into light pulses projected into the retina in real time.

In a clinical first, they were able to restore partial sight for the 58-year old patient, leaving him able to recognise, count, locate and touch different objects laid out on a table in front of him.

Jose-Alain Sahel, lead study author from France’s Sorbonne University and National Centre for Scientific Research, said the trial provided proof-of-concept confirmation that it was possible to use optogenetics to restore sight in humans.

“Importantly, blind patients with different kinds of neurodegenerative photoreceptor disease and a functional optic nerve will potentially be eligible for the treatment,” he said.

“However, it will take time until this therapy can be offered to patients,” added Sahel, who is also a professor at the University of Pittsburgh School of Medicine’s Department of Ophthalmology.

Published in Dawn, May 25th, 2021

Opinion

Editorial

Doctor attacked
09 Jun, 2026

Doctor attacked

AN act of reprehensible violence has shaken the medical community. On Saturday, an employee of the Provincial Civil...
AJK flare-up
Updated 09 Jun, 2026

AJK flare-up

The situation started deteriorating after a trader affiliated with the JAAC was reportedly shot in an altercation with law-enforcers.
Fault lines
09 Jun, 2026

Fault lines

THE April 8 ceasefire that halted hostilities between Israel and Iran has encountered its most serious test yet....
Soft on traders
08 Jun, 2026

Soft on traders

THE Fixed Tax Asaan Scheme for traders with an annual turnover of up to Rs200m has been designed as a ‘pragmatic...
Ceasefire in name
Updated 08 Jun, 2026

Ceasefire in name

Both sides accuse the other of violating the truce that was supposed to halt the conflict in April, yet neither appears willing to abandon negotiations altogether.
Damaged childhoods
08 Jun, 2026

Damaged childhoods

CHILD abuse is so prevalent that the UN ranked Pakistan as the least safe country for children. Even so, more than...